Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-380, HER2 inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-380 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-380, HER2 inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule. |
Key Inclusion Criteria (Part 1 and Part 2): * Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic breast cancer (Part 2). * Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standar...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-380 is an oral small molecule HER2 inhibitor being developed by Pfizer for the treatment of cancer. It is an investigational agent that has been studied in patients with advanced HER2-positive cancer. ARRY-380 is also known as an oral HER2 inhibitor.
ARRY-380 is being studied for use in cancer, specifically in patients with advanced HER2-positive cancer. It is an investigational therapy and has not been approved for any indication. Its development is focused on oncology.
ARRY-380 targets HER2, a receptor tyrosine kinase that is overexpressed in certain cancers. By inhibiting HER2, ARRY-380 may block signaling pathways that drive tumor growth. It is an oral small molecule designed to selectively inhibit HER2.
ARRY-380 is being developed by Pfizer, Inc. (ticker: PFE). Pfizer is responsible for the clinical development of this oral HER2 inhibitor.
ARRY-380 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial has been completed.
ARRY-380 has been studied in one completed Phase 1 clinical trial, NCT00650572, titled "A Study of ARRY-380 in Patients With Advanced HER2+ Cancer." The trial enrolled 50 patients in the United States and Canada.